DVAX
Closed
Dynavax Technologies Corporation
10.06
+0.14 (+1.41%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.92
Day's Range: 9.785 - 10.38
Send
sign up or login to leave a comment!
When Written:
9.81
Dynavax Technologies Corporation is a biopharmaceutical company that develops and commercializes novel vaccines and immunotherapeutic products. The company was founded in 1996 and is headquartered in Emeryville, California.
Dynavax's flagship product is HEPLISAV-B, a vaccine for the prevention of hepatitis B virus infection in adults. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in 2017 and is the only two-dose hepatitis B vaccine for adults.
In addition to HEPLISAV-B, Dynavax is also developing a pipeline of vaccines and immunotherapeutic products for the treatment of cancer and infectious diseases. The company's pipeline includes SD-101, an investigational cancer immunotherapy, and DV281, an investigational universal influenza vaccine.
Dynavax has partnerships and collaborations with a number of pharmaceutical companies and research institutions, including Merck & Co., AstraZeneca, and the University of Queensland. The company is publicly traded on the NASDAQ under the ticker symbol DVAX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Dynavax's flagship product is HEPLISAV-B, a vaccine for the prevention of hepatitis B virus infection in adults. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in 2017 and is the only two-dose hepatitis B vaccine for adults.
In addition to HEPLISAV-B, Dynavax is also developing a pipeline of vaccines and immunotherapeutic products for the treatment of cancer and infectious diseases. The company's pipeline includes SD-101, an investigational cancer immunotherapy, and DV281, an investigational universal influenza vaccine.
Dynavax has partnerships and collaborations with a number of pharmaceutical companies and research institutions, including Merck & Co., AstraZeneca, and the University of Queensland. The company is publicly traded on the NASDAQ under the ticker symbol DVAX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!